Marken continues their expansion of services in Latin America, by augmenting their GMP Compliant depot network with the newly purpose-built Buenos Aires facility.
“The expansion of our services in Latin America enables our clients to better recruit in treatment naïve populations and work with previously unreachable investigator sites, assuring quality and regulatory documentation through the entire supply chain.” said Wes Wheeler, Marken’s Chief Executive Officer.
Marken is implementing their stated plan and aims to build the most advanced, fit for purpose clinical distribution network to serve the pharmaceutical community. The new Argentina depot builds on Marken’s current Latin America business, and enables the company to grow from its life sciences logistics platform. Marken is developing further depot facilities in Europe, Asia and the Americas.
The Argentina depot joins Marken’s Mexico and Singapore depots offering the full range of temperature controlled storage capabilities including: controlled ambient, refrigerated (2º-8ºC), frozen (-20ºC) as well as a secured area for controlled substances. Each of Marken’s depots provides drug and equipment distribution solutions including: Pick & Pack, relabeling services, reverse logistics, reconciliation and certified destruction. Additionally the network manages specimen kit distribution, interim specimen storage and management.
Telemedicine Considerations When Conducting Decentralized Clinical Trials
January 14th 2025Compliance with state telemedicine requirements is imperative, as not only will most clinical trial sponsors contractually require such compliance, but non-compliance may also subject the practitioner to licensure violations and liability.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.